This would not only explain the gain in chromatin accessibility at NFκB and NR4A1 consensus sites and the lack of DNA-bound NOTCH3/CSL complexes in response to gliotoxin treatment, but also the NOTCH3-dependent NR4A1 gene activity in CLL cells. This evidence concerns the gene NOTCH3 and B-cell chronic lymphocytic leukemia.